Reference
- Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59(8):1540-1548.
The Authors Respond
Thank you for your comments. We were concerned that the article was already too long for ACEP Now and tried to limit it to salient points regarding the clinical management of seizures in the pediatric patient in the acute setting.
Explore This Issue
ACEP Now: Vol 38 – No 04 – April 2019That said, the role of cannabinoids in the management of seizures may very well be enhanced in upcoming years. The approval by the FDA of oral cannabidiol oral solution in the management of seizures associated with Dravet and Lennox-Gestaut syndromes in children over the age of two in June 2018 was certainly a start.
Boris Garber, DO, FACEP
Jonathan Glauser, MD, MBA, FACEP
Pages: 1 2 | Single Page
No Responses to “Readers Note Shortcoming in Pediatric Seizure Article, Authors Respond”